Cancer Family
Ovarian Epithelial Tumor
CI-CAN-00000305Explore in graph →
Non-malignant271 active trials2 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000305Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | terminated | Phase 2 / Phase 3 | 600 | Sutro Biopharma, Inc.INDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT05092360 | Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)(ARTISTRY-7) | terminated | Phase 3 | 456 | Mural Oncology, Inc |
| 14 |
| Aug 28, 2025 |
| clinicaltrials |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | terminated | Phase 2 / Phase 3 | 11 | University Health Network, TorontoOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer | terminated | Phase 2 / Phase 3 | 70 | Mateon TherapeuticsINDUSTRY | 3 | Mar 24, 2025 | clinicaltrials |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | terminated | Phase 3 | 86 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04729608 | Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer(AXLerate-OC) | terminated | Phase 3 | 366 | Aravive, Inc.INDUSTRY | 11 | Oct 30, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT03690739 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | terminated | Phase 3 | 9 | AGO Research GmbHINDUSTRY | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01840943 | A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy | terminated | Phase 3 | 32 | Xian-Janssen Pharmaceutical Ltd.INDUSTRY | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00047632 | Safety and Efficacy of Interferon Gamma-1b Plus Chemotherapy for Ovarian and Peritoneal Cancer | terminated | Phase 3 | 847 | InterMuneINDUSTRY | 1 | Nov 1, 2007 | clinicaltrials |
| NCT00189371 | Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum | terminated | Phase 3 | 300 | AGO Study GroupOTHER | 1 | Sep 19, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 23, 2025source: clinicaltrials